Cue Biopharma, Inc.
CUE
$30.50
$0.501.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 37.65M | 32.73M | 27.47M | 7.10M | 8.29M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.65M | 32.73M | 27.47M | 7.10M | 8.29M |
| Cost of Revenue | 74.99M | 33.59M | 34.84M | 25.30M | 29.62M |
| Gross Profit | -37.34M | -862.00K | -7.38M | -18.20M | -21.34M |
| SG&A Expenses | 61.31M | 18.72M | 19.14M | 19.91M | 18.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 136.30M | 52.32M | 53.99M | 45.21M | 47.76M |
| Operating Income | -98.64M | -19.58M | -26.52M | -38.11M | -39.48M |
| Income Before Tax | -163.61M | -19.02M | -26.10M | -37.68M | -38.90M |
| Income Tax Expenses | 500.00K | 500.00K | 500.00K | -- | -- |
| Earnings from Continuing Operations | -164.11 | -19.52 | -26.60 | -37.68 | -38.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -164.11M | -19.52M | -26.60M | -37.68M | -38.90M |
| EBIT | -98.64M | -19.58M | -26.52M | -38.11M | -39.48M |
| EBITDA | -97.28M | -18.16M | -25.56M | -37.73M | -39.08M |
| EPS Basic | -26.99 | -5.52 | -9.39 | -13.67 | -16.53 |
| Normalized Basic EPS | -16.78 | -3.36 | -5.78 | -8.53 | -10.36 |
| EPS Diluted | -27.00 | -5.53 | -9.40 | -13.67 | -16.53 |
| Normalized Diluted EPS | -16.79 | -3.37 | -5.79 | -8.53 | -10.36 |
| Average Basic Shares Outstanding | 18.11M | 14.95M | 12.62M | 11.49M | 9.84M |
| Average Diluted Shares Outstanding | 18.19M | 15.04M | 12.70M | 11.49M | 9.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |